#China #Shanghai #Climate Change #WuXi Biologics #water security

WuXi Biologics Achieves Top CDP Ratings for Sustainability

WuXi Biologics, a recognized global leader in biopharmaceutical solutions, has recently announced a significant achievement: it has earned the esteemed "A" ratings from CDP in both Climate Change and Water Security for the year 2025. This accomplishment reflects the company's commitment to environmental sustainability and transparent practices in managing ecological challenges.

Commitment to Climate Change

WuXi Biologics' recognition by the CDP for Climate Change underlines its proactive stance in environmental performance. Their strategy, acknowledged by the Science Based Targets initiative (SBTi), directs efforts towards net-zero greenhouse gas emissions across its entire value chain by 2050. This ambitious goal is supported by a meticulously crafted roadmap and various initiatives aimed at energy efficiency, process optimization, and renewable energy adoption. Impressively, WuXi Biologics’ biologics facility in Ireland operates solely on renewable electricity, showcasing a substantial step towards reducing the environmental impact of their operations.

Water Security Initiatives

Achieving a spot on the CDP Water Security "A" List for the third consecutive year further emphasizes WuXi Biologics' efforts in sustainable water management. The company lays out a detailed framework aligned with the United Nations Sustainable Development Goal (SDG) 6, focusing on water governance, quality, and conservation. WuXi Biologics has set a target to decrease water consumption per unit of production by 30% by the end of 2025 compared to 2019 levels. One significant initiative in this area is the launch of their Water Excellence Stewardship (WES) program, which addresses crucial aspects of water management, including water quality and personal hygiene safety measures.

Partnership for Change

Earlier this year, WuXi Biologics also received an "A" rating in the CDP Supplier Engagement assessment, recognizing its commitment to engaging suppliers in climate action. The company actively collaborates with its global supply chain to drive a transition towards a net-zero and sustainable economy. This is achieved through a sophisticated sustainable supply chain management system that tracks emissions and sets targets for improvement.

Dr. Chris Chen, the CEO of WuXi Biologics, expressed his pride in these achievements, saying, "The ratings from CDP affirm our continuous efforts in Climate Change and Water Security. As a leader in the green biologics sector, we aim to inspire and steer the industry toward a more sustainable future."

Recognitions and Initiatives

WuXi Biologics' sustainability efforts have not gone unnoticed. The company is a participant in the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), advocating for sustainable practices and earning accolades including an MSCI AAA rating, the EcoVadis Platinum Medal, and recognition in the Dow Jones Sustainability Indices (DJSI). Furthermore, it has been rated as a top company in various ESG metrics for five consecutive years and holds a position in the FTSE4Good Index Series and the Hang Seng ESG 50 Index.

About WuXi Biologics

As a major player in Contract Research, Development, and Manufacturing Organization (CRDMO), WuXi Biologics provides comprehensive solutions that aid partners in the discovery, development, and manufacturing of biologics, benefiting global health. With over 12,000 professionals across locations in China, the US, Ireland, Germany, and Singapore, the company manages ongoing support for 864 integrated client projects, 24 of which are in commercial production, emphasizing its commitment to quality and innovation.

In conclusion, WuXi Biologics exemplifies how corporate responsibility and sustainability can be integrated into the core business strategy, creating shared value for all stakeholders while fostering a healthier planet.